Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 2703 

U.S. consumers and businesses, 

including for-profit and not-for-profit 

enterprises, and federal, state, and local 

government agencies. The aggregate 

estimates produced from the survey data 

are widely cited in academic working 

papers, journal articles, and industry 

publications; reported in the media; and 

used by the public, industry, and policy 

makers as a quantitative aggregate 

benchmark of noncash payments and 

cash withdrawal and deposit activity in 

the United States. 

Frequency: Annually. 

Respondents: Organizations with a 

significant role in processing payments, 

including depository and financial 

institutions, general-purpose payment 

networks, third-party payment 

processors, issuers of private-label 

payment instruments, and providers of 

various alternative payment methods 

and systems. 

Total estimated number of 

respondents: FR 3066a, 513, FR 3066b, 

170. 

Estimated average hours per response: 

FR 3066a, 22; FR 3066b, 8. 

Total estimated annual burden hours: 

12,646. 

Current actions: On July 30, 2024, the 

Board published a notice in the Federal 

Register (89 FR 61116) requesting 

public comment for 60 days on the 

extension, without revision, of the FR 

3066. The comment period for this 

notice expired on September 30, 2024. 

The Board received one comment. 

Detailed Discussion of Public 

Comments 

The Board received one public 

comment from a payments industry 

association. The commenter was 

supportive of renewing and continuing 

this information collection. The 

commenter also urged the Board to 

publish timely and comprehensive 

results from the FRPS. 

The Board strives to release detailed 

results from the FRPS expeditiously. 

Both the Board and FRB Atlanta are 

working continuously to improve both 

the quality and the timing of FRPS 

releases. The Board intends to publish 

any releases as soon as practicable with 

the goal of making information available 

while not sacrificing the quality and 

accuracy of that information. Achieving 

the necessary quality standard for 

detailed data is particularly important 

when constructing national estimates 

upon which policymakers, the industry, 

and the public can rely. 

To that end, the Board expects to 

continue the practice of releasing results 

in stages, with an initial release of 

topline estimates followed by more 

extensive detailed releases at a later 

stage. Results from annual supplements 

will periodically complement the initial 

and detailed triennial releases. Focused 

reports or releases on specific topics 

may also be published periodically. The 

Board has released some detailed data 

for the 2022 Federal Reserve Payments 

Study and 2023 Annual Supplement, 

and more is expected to be released in 

the near future. 

The Board has adopted the extension, 

without revision, of the FR 3066 as 

originally proposed. 

Board of Governors of the Federal Reserve 

System, January 7, 2025. 

Benjamin W. McDonough, 

Deputy Secretary and Ombuds of the Board. 

[FR Doc. 2025–00482 Filed 1–10–25; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, pursuant to Public Law 92– 

463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP25–038, Epilepsy Incidence Among 

Children in the United States. 

Date: March 19, 2025. 

Time: 10 a.m.–6 p.m., EDT. 

Place: Teleconference/Web 

Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Catherine Barrett, Ph.D., Scientific 

Review Officer, National Center for 

Chronic Disease Prevention and Health 

Promotion, Centers for Disease Control 

and Prevention, 4770 Buford Highway, 

Mailstop S106–3, Atlanta, Georgia 

30341–3717. Telephone: (404) 718– 

7664; Email: CBarrett@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2025–00491 Filed 1–10–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, pursuant to Public Law 92– 

463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP25–043, Comprehensive Analysis, 

Surveillance, and Statistics Initiative for 

Diabetes in the Young (CASSIDY). 

Date: March 12, 2025. 

Time: 10 a.m.–6 p.m., EDT. 

Place: Teleconference/Web 

Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Natalie Brown, M.P.H., Scientific 

Review Officer, National Center for 

Chronic Disease Prevention and Health 

Promotion, Centers for Disease Control 

and Prevention, 4770 Buford Highway, 

Mailstop S106–3, Atlanta, Georgia 

30341–3717. Telephone: (404) 639– 

4601; Email: NBrown3@cdc.gov. 


ddrumheller on DSK120RN23PROD with NOTICES1
2704 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2025–00492 Filed 1–10–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, pursuant to Public Law 92– 

463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP25–041, Connecting Organizations 

and People to Empower Diabetes 

Prevention and Treatment 

(Connections). 

Date: March 11, 2025. 

Time: 10 a.m.–6 p.m., EDT. 

Place: Teleconference/Web 

Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Catherine Barrett, Ph.D., Scientific 

Review Officer, National Center for 

Chronic Disease Prevention and Health 

Promotion, Centers for Disease Control 

and Prevention, 4770 Buford Highway, 

Mailstop S106–3, Atlanta, Georgia 

30341–3717. Telephone: (404) 718– 

7664; Email: CBarrett@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2025–00488 Filed 1–10–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, pursuant to Public Law 92– 

463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–OH–24–002, Exploratory/ 

Developmental Grants on Lifestyle 

Medicine Research Related to the World 

Trade Center Health Program (R21); 

RFA–OH–24–003, Exploratory/ 

Developmental Grants Related to the 

World Trade Center Survivors (R21-No 

Applications with Responders 

Accepted); RFA–OH–24–004, World 

Trade Center Health Program Mentored 

Research Scientist Career Development 

Award (K01); and RFA–OH–25–001, 

Exploratory/Developmental Research for 

World Trade Center Health Program 

Evidence-based Strategies to Improve 

Treatment Effectiveness, Diagnostic 

Practices, and Program Evaluation 

(R21). 

Dates and Times: February 25, 2025, 

9 a.m.–5 p.m., EST; and February 26, 

2025, 9 a.m.–12 p.m., EST. 

Place: Courtyard by Marriott Atlanta 

Decatur Downtown/Emory, 130 

Clairemont Avenue, Decatur, Georgia 

30030. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Laurel Garrison, M.P.H., Scientific 

Review Officer, Office of Extramural 

Coordination and Special Projects, 

National Institute for Occupational 

Safety and Health, Centers for Disease 

Control and Prevention, 5555 Ridge 

Avenue, Cincinnati, Ohio 45213. 

Telephone: (513) 533–8324; Email: 

LGarrison@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2025–00487 Filed 1–10–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–25–1385] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Characteristics 

of Cases of Priority Fungal Diseases’’ to 

the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on October 25, 2024, to obtain 

comments from the public and affected 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 


ddrumheller on DSK120RN23PROD with NOTICES1